NasdaqGM:PRCTMedical Equipment
Assessing PROCEPT BioRobotics (PRCT) Valuation As Fresh Analyst Downgrade Meets Confident Long-Term Growth Views
PROCEPT BioRobotics (PRCT) is back in focus after a flurry of analyst updates, including a downgrade from Bank of America that sits alongside more optimistic views on future utilization and long-term market potential.
See our latest analysis for PROCEPT BioRobotics.
The recent analyst flurry comes after a choppy stretch for PROCEPT BioRobotics, with a 7 day share price return of 6.73% following a 1 day decline of 4.79% and a 1 year total shareholder return of 62.20% in the red. This suggests...